- Trials with a EudraCT protocol (50)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
50 result(s) found for: Real-time data.
Displaying page 1 of 3.
EudraCT Number: 2021-002635-35 | Sponsor Protocol Number: Ph2_INBRX-109_SA_CS | Start Date*: 2022-02-11 | |||||||||||
Sponsor Name:Inhibrx, Inc. | |||||||||||||
Full Title: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma | |||||||||||||
Medical condition: Unresectable or metastatic conventional chondrosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Restarted) IT (Trial now transitioned) IE (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000106-37 | Sponsor Protocol Number: 37.07.-92906 | Start Date*: 2008-08-28 | |||||||||||
Sponsor Name:Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital | |||||||||||||
Full Title: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris | |||||||||||||
Medical condition: Psoriasis vulgaris (Plaque-Typ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001721-31 | Sponsor Protocol Number: SPON-AK-0420 | Start Date*: 2020-05-01 | |||||||||||
Sponsor Name:Hampshire Hospitals NHS TRust | |||||||||||||
Full Title: Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals? | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001224-33 | Sponsor Protocol Number: COV-HCQ | Start Date*: 2020-03-25 | |||||||||||
Sponsor Name:Universitätsklinikum Tübingen | |||||||||||||
Full Title: Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19 | |||||||||||||
Medical condition: Acute coronavirus disease 2019 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001677-31 | Sponsor Protocol Number: AMB-001 | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in peop... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000179-18 | Sponsor Protocol Number: RG_13-322 | Start Date*: 2015-04-28 |
Sponsor Name:University of Birmingham [...] | ||
Full Title: Local Oestrogen Treatment in Postmenopausal Women Undergoing Pelvic Organ Prolapse Surgery (LOTUS) - Feasibility Study | ||
Medical condition: Pelvic organ prolapse | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001760-29 | Sponsor Protocol Number: ALCOVID-19 | Start Date*: 2020-09-09 |
Sponsor Name:Sociedad Española de Farmacia Hospitalaria | ||
Full Title: Phase II clinical trial to evaluate the efficacy and safety of inhaled ethanol in the treatment of early-stage COVID-19. | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003541-15 | Sponsor Protocol Number: 2019-Fungi | Start Date*: 2020-02-19 | |||||||||||
Sponsor Name:Aarhus University | |||||||||||||
Full Title: Adjunct effect of fluconazole in the treatment of Candida-associated refractory severe periodontitis – A single-center, placebo-controlled, triple blind, randomized clinical trial | |||||||||||||
Medical condition: Periodontitis. The participants are in good general health, but have at least 2 residual dental lesions after periodontal treatment (standard care). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002779-12 | Sponsor Protocol Number: 10968 | Start Date*: 2023-02-06 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Real-time margin assessment in head and neck cancer – enhancing specificity by combining fresh frozen sectioning with targeted fluorescence imaging The LIGHTNING study | ||
Medical condition: Head and neck cancer for which surgical excision has been determined by the multidisciplinary tumor board | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002217-59 | Sponsor Protocol Number: 63623872FLZ3002 | Start Date*: 2018-05-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, ... | |||||||||||||
Medical condition: Influenza A Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) EE (Completed) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) BE (Completed) BG (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000969-47 | Sponsor Protocol Number: 13702908 | Start Date*: 2014-07-04 | |||||||||||
Sponsor Name:University Hospital of Toulouse | |||||||||||||
Full Title: Clinical efficacy of coordinated boluses in type 1 diabetic patients treated with insulin pumps: a multicentric, randomised, cross over study (COBOL study). | |||||||||||||
Medical condition: type 1 diabetic patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000359-26 | Sponsor Protocol Number: ESTEVE-SANF-201 | Start Date*: 2016-04-29 |
Sponsor Name:Laboratorios del Dr. Esteve, S.A. | ||
Full Title: Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients wit... | ||
Medical condition: Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome) is an inherited lysosomal storage disease caused by a specific lysosomal enzyme deficiency that leads to intracellular accumulation of the ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022422-32 | Sponsor Protocol Number: RHMCAN0749 | Start Date*: 2010-12-20 |
Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||
Full Title: A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib | ||
Medical condition: Diffuse Large B-cell Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004864-69 | Sponsor Protocol Number: HSJD-HR-NB-Ch14.18 | Start Date*: 2014-05-21 | |||||||||||
Sponsor Name:Fundació Sant Joan de Deu de Barcelona | |||||||||||||
Full Title: Phase II single arm institutional study to assess Dinutuximab combined with the cytokines granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-2 in patients with high-risk neuroblastoma... | |||||||||||||
Medical condition: High-risk neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010140-33 | Sponsor Protocol Number: SPON672-09 | Start Date*: 2009-11-13 |
Sponsor Name:Cardiff University | ||
Full Title: A randomised phase II Trial of carboplatin and gemcitabine +/- vandetanib in first line treatment Of advanced Urothelial cell Cancer in patients who are not suitable to receive cisplatin | ||
Medical condition: Transitional cell carcinoma of urothelium (upper or lower urinary tract). Cancers with other pathologies are permitted, provided that the dominant morphology is transitional cell carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016489-10 | Sponsor Protocol Number: TPF-C-HIT | Start Date*: 2010-08-23 |
Sponsor Name:University of Heidelberg | ||
Full Title: Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanc... | ||
Medical condition: The study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001992-30 | Sponsor Protocol Number: | Start Date*: 2015-04-20 | |||||||||||
Sponsor Name:University of Leicester | |||||||||||||
Full Title: A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma | |||||||||||||
Medical condition: Histologically confirmed malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003755-41 | Sponsor Protocol Number: ERIS | Start Date*: 2021-10-12 |
Sponsor Name:Region Skåne | ||
Full Title: ERIS- EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study | ||
Medical condition: EGFR-mutated non-small cell lung cancer (NSCLC) not amenable for curative treatment intention and candidates for EGFR-inhibitor in first line. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012807-25 | Sponsor Protocol Number: IIL-MCL0208 | Start Date*: 2010-01-28 | ||||||||||||||||||||||||||
Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS | ||||||||||||||||||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY A... | ||||||||||||||||||||||||||||
Medical condition: Mantel cell lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) PT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004308-11 | Sponsor Protocol Number: GTG002.07 | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:Genethon | |||||||||||||
Full Title: PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME | |||||||||||||
Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopenia,... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
